PMID: 9555782DOI: 10.1016/s0002-9149(98)00010-1Apr 29, 1998Paper
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group
The American Journal of Cardiology
J C FruchartE Leitersdorf
Abstract
The hypolipidemic action of fibrates has recently been shown to involve the activation of peroxisome proliferator activated receptors establishing a molecular mechanism for this class of drugs. Increasing clinical trial evidence supports the efficacy of fibrates in the treatment of dyslipoproteinemias, particularly in patients with hypertriglyceridemia and low high-density lipoproteins.
Citations
May 11, 2000·Lupus·A S Wierzbicki
Aug 10, 2000·Drugs·P H Chong, B S Bachenheimer
Feb 28, 2001·FEBS Letters·F P ManciniF Goglia
May 10, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·Behzad MolaviJawahar L Mehta
Sep 21, 2002·Current Medical Research and Opinion·Moses Elisaf
Jul 2, 2002·Journal of Lipid Research·B KalderonJ Bar-Tana
Oct 23, 2002·Pharmacotherapy·Jim Koeller, Robert L Talbert
Aug 13, 2003·Current Atherosclerosis Reports·Antonios M Xydakis, Peter H Jones
Jun 20, 2003·Current Medical Research and Opinion·A S WierzbickiC B Byrne
Aug 22, 2003·Drugs·Martin Hersberger, Arnold von Eckardstein
Mar 10, 2004·Current Medical Research and Opinion·UNKNOWN UK HDL-C Consensus Group
Mar 20, 2004·Expert Review of Cardiovascular Therapy·Michael H Davidson
Jul 31, 2004·Drug Metabolism and Drug Interactions·Hideki FujinoJunji Kojima
Sep 15, 2005·Journal of Cardiovascular Pharmacology·Hong Sook KoWang Seong Ryu
Jun 25, 2005·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Jeffrey M PetersFrank J Gonzalez
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Michel Farnier
Aug 29, 2007·International Journal of Nanomedicine·Konstantinos Tziomalos, Vasilios G Athyros
Nov 26, 2009·The Annals of Pharmacotherapy·Martin HahnM Shawn McFarland
Sep 28, 2010·PPAR Research·Michung Yoon
Mar 13, 1999·Current Opinion in Lipidology·M H Dominiczak
Oct 26, 1999·The Annals of Pharmacotherapy·D R Guay
Nov 14, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·T B TwicklerD W Erkelens
Nov 22, 2000·Current Opinion in Lipidology·O Faergeman
Feb 19, 2000·Current Opinion in Lipidology·G F Watts, S B Dimmitt
Jul 4, 2002·Current Medical Research and Opinion·George LiamisMoses Elisaf
May 25, 2002·Drugs & Aging·Michael H DavidsonKate A Ingram
Oct 23, 2002·Journal of General Internal Medicine·Michael L Green
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·I J JonkersA van der Laarse
May 1, 2004·Circulation·T B TwicklerM J Chapman
Sep 29, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Juan F AscasoUNKNOWN HDL Forum
Oct 17, 2006·Medicinski pregled·Vid StanulovićJovan Popović
Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen
Jun 15, 2007·Obesity·Sunhyo Jeong, Michung Yoon
Feb 14, 2006·Proteomics·Jean-François LéonardJean-Charles Gautier
Jul 16, 2008·Expert Opinion on Therapeutic Targets·Ekaterini Vourvouhaki, George V Dedoussis
Sep 9, 2008·Journal of Atherosclerosis and Thrombosis·Tamio TeramotoMasayuki Yokode
Dec 3, 2009·The Journal of Toxicological Sciences·Toshihiko MakinoHiroyuki Nakayama
Oct 16, 2012·Molecular Biology Reports·Jun HeLizhi Lu
Jan 4, 2012·Current Cardiology Reports·Paul D Rosenblit
Aug 2, 2013·Diabetes Care·Roy EldorMuhammad Abdul-Ghani
Nov 14, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M P DubéUNKNOWN Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
May 23, 2002·The Journal of Pharmacology and Experimental Therapeutics·Thomayant PrueksaritanontThomas A Baillie
May 26, 2005·Current Treatment Options in Cardiovascular Medicine·Richard L Dunbar, Daniel J Rader
Aug 22, 2006·Expert Review of Cardiovascular Therapy·Jennifer G Robinson, Michael H Davidson
Apr 17, 2008·Cardiology in Review·Joshua RemickArthur Schwartzbard
Jul 24, 2008·Current Treatment Options in Cardiovascular Medicine·Ameen F Person, Cam Patterson
May 26, 2007·Clinical Drug Investigation·C StefanuttiA Mammarella
Sep 12, 2008·Clinical Drug Investigation·Michael H Davidson, Peter H Jones
Sep 24, 2008·Expert Opinion on Investigational Drugs·Theodosios Filippatos, Haralampos J Milionis
Oct 21, 2010·Expert Opinion on Pharmacotherapy·Giovanni Battista Vigna, Renato Fellin
Feb 11, 2016·European Journal of Gastroenterology & Hepatology·Li WangXuan Zhang
❮ Previous
Next ❯
Related Concepts
Related Feeds
Cardiovascular Diseases: Risk Factors
Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.
Related Papers
Trends in Pharmacological Sciences
G J Murphy, J C Holder
BMC Bioinformatics
Lei GuoYvonne P Dragan
Journal de la Société de biologie
J C FruchartBart Staels
Drug News & Perspectives
Ranjan Mukherjee